FEMY vs. NMTC, RVP, POCI, IINN, MODD, LNSR, MDAI, DRIO, PYPD, and NEPH
Should you be buying Femasys stock or one of its competitors? The main competitors of Femasys include NeuroOne Medical Technologies (NMTC), Retractable Technologies (RVP), Precision Optics (POCI), Inspira Technologies Oxy B.H.N. (IINN), Modular Medical (MODD), LENSAR (LNSR), Spectral AI (MDAI), DarioHealth (DRIO), PolyPid (PYPD), and Nephros (NEPH). These companies are all part of the "medical" sector.
Femasys (NASDAQ:FEMY) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Femasys presently has a consensus target price of $11.33, indicating a potential upside of 752.13%. NeuroOne Medical Technologies has a consensus target price of $2.20, indicating a potential upside of 89.66%. Given Femasys' higher possible upside, equities research analysts clearly believe Femasys is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies received 42 more outperform votes than Femasys when rated by MarketBeat users. Likewise, 71.59% of users gave NeuroOne Medical Technologies an outperform vote while only 63.64% of users gave Femasys an outperform vote.
In the previous week, Femasys had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 2 mentions for Femasys and 0 mentions for NeuroOne Medical Technologies. Femasys' average media sentiment score of 0.69 beat NeuroOne Medical Technologies' score of 0.00 indicating that Femasys is being referred to more favorably in the media.
Femasys has a beta of -3, indicating that its stock price is 400% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
NeuroOne Medical Technologies has a net margin of -478.41% compared to Femasys' net margin of -1,329.10%. Femasys' return on equity of -105.47% beat NeuroOne Medical Technologies' return on equity.
65.3% of Femasys shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 16.4% of Femasys shares are owned by company insiders. Comparatively, 7.5% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
NeuroOne Medical Technologies has higher revenue and earnings than Femasys. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.
Summary
Femasys beats NeuroOne Medical Technologies on 10 of the 17 factors compared between the two stocks.
Get Femasys News Delivered to You Automatically
Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
